vs
勃肯（BIRK）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是勃肯的1.5倍（$772.1M vs $526.3M），勃肯净利率更高（19.3% vs 12.7%，领先6.5%），过去两年勃肯的营收复合增速更高（26.8% vs 9.0%）
勃肯是源自德国的知名鞋履制造商，1774年成立，总部位于莱茵兰-普法尔茨州维德河畔诺伊施塔特。品牌标志性产品采用麂皮、黄麻层叠打造的弧形软木鞋垫，可贴合穿着者脚型，尤以舒适凉鞋品类闻名，创立初衷是为替代当时普遍的平底鞋，推出兼具支撑性与贴合度的鞋款。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BIRK vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$526.3M
净利率更高
BIRK
高出6.5%
12.7%
两年增速更快
BIRK
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $526.3M | $772.1M |
| 净利润 | $101.4M | $98.4M |
| 毛利率 | 62.8% | — |
| 营业利润率 | 23.0% | 14.5% |
| 净利率 | 19.3% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIRKRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $526.3M | $698.9M | ||
| Q2 25 | $685.8M | $720.3M | ||
| Q1 25 | $620.3M | $664.8M | ||
| Q4 24 | $390.7M | $729.4M | ||
| Q3 24 | $455.8M | $684.0M | ||
| Q2 24 | $609.9M | $691.7M | ||
| Q1 24 | $519.7M | $649.9M |
净利润BIRKRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $101.4M | $46.7M | ||
| Q2 25 | $139.6M | $53.9M | ||
| Q1 25 | $113.5M | $42.2M | ||
| Q4 24 | $21.7M | $94.6M | ||
| Q3 24 | — | $94.4M | ||
| Q2 24 | $80.6M | $55.4M | ||
| Q1 24 | $77.4M | $26.0M |
毛利率BIRKRVTY
| Q4 25 | — | — | ||
| Q3 25 | 62.8% | 53.6% | ||
| Q2 25 | 60.5% | 54.5% | ||
| Q1 25 | 57.7% | 56.5% | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | 59.5% | 55.7% | ||
| Q1 24 | 56.3% | 54.6% |
营业利润率BIRKRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 23.0% | 11.7% | ||
| Q2 25 | 31.2% | 12.6% | ||
| Q1 25 | 30.5% | 10.9% | ||
| Q4 24 | 17.7% | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | 27.5% | 12.4% | ||
| Q1 24 | 27.5% | 6.8% |
净利率BIRKRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 19.3% | 6.7% | ||
| Q2 25 | 20.3% | 7.5% | ||
| Q1 25 | 18.3% | 6.4% | ||
| Q4 24 | 5.6% | 13.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | 13.2% | 8.0% | ||
| Q1 24 | 14.9% | 4.0% |
每股收益（稀释后）BIRKRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $355.4M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $7.3B |
| 总资产 | $5.3B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIRKRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $355.4M | $931.4M | ||
| Q2 25 | $282.8M | $991.8M | ||
| Q1 25 | $254.2M | $1.1B | ||
| Q4 24 | $322.5M | $1.2B | ||
| Q3 24 | $384.3M | $1.2B | ||
| Q2 24 | $436.7M | $2.0B | ||
| Q1 24 | $189.8M | $1.7B |
股东权益BIRKRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $2.9B | $7.4B | ||
| Q2 25 | $2.8B | $7.6B | ||
| Q1 25 | $3.0B | $7.6B | ||
| Q4 24 | $3.0B | $7.7B | ||
| Q3 24 | $2.8B | $7.9B | ||
| Q2 24 | $2.8B | $7.9B | ||
| Q1 24 | $2.7B | $7.8B |
总资产BIRKRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $5.3B | $12.1B | ||
| Q2 25 | $5.3B | $12.4B | ||
| Q1 25 | $5.4B | $12.4B | ||
| Q4 24 | $5.4B | $12.4B | ||
| Q3 24 | $5.3B | $12.8B | ||
| Q2 24 | $5.4B | $13.4B | ||
| Q1 24 | $5.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $415.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 4.09× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流BIRKRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $415.0M | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | $-12.6M | $174.2M | ||
| Q3 24 | $463.0M | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流BIRKRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率BIRKRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度BIRKRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率BIRKRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 4.09× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | -0.58× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIRK
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
